488 related articles for article (PubMed ID: 17554117)
1. Natural history and outcome in systemic AA amyloidosis.
Lachmann HJ; Goodman HJ; Gilbertson JA; Gallimore JR; Sabin CA; Gillmore JD; Hawkins PN
N Engl J Med; 2007 Jun; 356(23):2361-71. PubMed ID: 17554117
[TBL] [Abstract][Full Text] [Related]
2. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.
Gillmore JD; Lovat LB; Persey MR; Pepys MB; Hawkins PN
Lancet; 2001 Jul; 358(9275):24-9. PubMed ID: 11454373
[TBL] [Abstract][Full Text] [Related]
3. AA amyloidosis complicating the hereditary periodic fever syndromes.
Lane T; Loeffler JM; Rowczenio DM; Gilbertson JA; Bybee A; Russell TL; Gillmore JD; Wechalekar AD; Hawkins PN; Lachmann HJ
Arthritis Rheum; 2013 Apr; 65(4):1116-21. PubMed ID: 23280696
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.
Lane T; Gillmore JD; Wechalekar AD; Hawkins PN; Lachmann HJ
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S46-53. PubMed ID: 26120866
[TBL] [Abstract][Full Text] [Related]
5. French practical guidelines for the diagnosis and management of AA amyloidosis.
Georgin-Lavialle S; Savey L; Buob D; Bastard JP; Fellahi S; Karras A; Boffa JJ; Grateau G; ; Audard V; Bridoux F; Damade R; Deshayes S; Giurgea I; Granel B; Hachulla E; Hot A; Jaccard A; Knebelmann B; Marciano S; Pelcot F; Sarrabay G; Boursier G; Sellam J; Terre A; Bourguiba R
Rev Med Interne; 2023 Feb; 44(2):62-71. PubMed ID: 36759076
[TBL] [Abstract][Full Text] [Related]
6. Eprodisate for the treatment of renal disease in AA amyloidosis.
Dember LM; Hawkins PN; Hazenberg BP; Gorevic PD; Merlini G; Butrimiene I; Livneh A; Lesnyak O; Puéchal X; Lachmann HJ; Obici L; Balshaw R; Garceau D; Hauck W; Skinner M;
N Engl J Med; 2007 Jun; 356(23):2349-60. PubMed ID: 17554116
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and survival in AA amyloidosis patients.
Ayar Y; Ersoy A; Oksuz MF; Ocakoglu G; Vuruskan BA; Yildiz A; Isiktas E; Oruc A; Celikci S; Arslan I; Sahin AB; Güllülü M
Rev Bras Reumatol Engl Ed; 2017; 57(6):535-544. PubMed ID: 29173691
[TBL] [Abstract][Full Text] [Related]
8. Pathogenetic mechanisms of amyloid A amyloidosis.
Simons JP; Al-Shawi R; Ellmerich S; Speck I; Aslam S; Hutchinson WL; Mangione PP; Disterer P; Gilbertson JA; Hunt T; Millar DJ; Minogue S; Bodin K; Pepys MB; Hawkins PN
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16115-20. PubMed ID: 23959890
[TBL] [Abstract][Full Text] [Related]
9. Secondary, AA, Amyloidosis.
Papa R; Lachmann HJ
Rheum Dis Clin North Am; 2018 Nov; 44(4):585-603. PubMed ID: 30274625
[TBL] [Abstract][Full Text] [Related]
10. Amyloid A Amyloidosis After Renal Transplantation: An Important Cause of Mortality.
Sarihan I; Caliskan Y; Mirioglu S; Ozluk Y; Senates B; Seyahi N; Basturk T; Yildiz A; Kilicaslan I; Sever MS
Transplantation; 2020 Aug; 104(8):1703-1711. PubMed ID: 32732850
[TBL] [Abstract][Full Text] [Related]
11. AA amyloidosis: basic knowledge, unmet needs and future treatments.
Obici L; Merlini G
Swiss Med Wkly; 2012; 142():w13580. PubMed ID: 22653707
[TBL] [Abstract][Full Text] [Related]
12. Systemic AA amyloidosis.
Pinney JH; Lachmann HJ
Subcell Biochem; 2012; 65():541-64. PubMed ID: 23225016
[TBL] [Abstract][Full Text] [Related]
13. Amyloid storm: acute kidney injury and massive proteinuria, rapidly progressing to end-stage kidney disease in AA amyloidosis of familial Mediterranean fever.
Kukuy OL; Beckerman P; Dinour D; Ben-Zvi I; Livneh A
Rheumatology (Oxford); 2021 Jul; 60(7):3235-3242. PubMed ID: 33291151
[TBL] [Abstract][Full Text] [Related]
14. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis.
Migita K; Eguchi K; Tsukada T; Kawabe Y; Takashima H; Mine M; Aoyagi T; Ichinose Y; Nagataki S
Lab Invest; 1996 Sep; 75(3):371-5. PubMed ID: 8804360
[TBL] [Abstract][Full Text] [Related]
15. Deposition, Clearance, and Reinduction of Amyloid A Amyloid in Interleukin 1 Receptor Antagonist Knockout Mice.
Watanabe K; Uchida K; Chambers JK; Ushio N; Nakayama H
Vet Pathol; 2017 Jan; 54(1):99-110. PubMed ID: 27565681
[TBL] [Abstract][Full Text] [Related]
16. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis.
Perry ME; Stirling A; Hunter JA
Clin Rheumatol; 2008 Jul; 27(7):923-5. PubMed ID: 18379834
[TBL] [Abstract][Full Text] [Related]
17. The value of the levels of acute phase reactants for the prediction of familial Mediterranean fever associated amyloidosis: a case control study.
Yalçinkaya F; Cakar N; Acar B; Tutar E; Güriz H; Elhan AH; Oztürk S; Kansu A; Ince E; Atalay S; Girgin N; Doğru U; Aysev D; Ekim M
Rheumatol Int; 2007 Apr; 27(6):517-22. PubMed ID: 17103173
[TBL] [Abstract][Full Text] [Related]
18. Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome.
van der Hilst JC; Drenth JP; Bodar EJ; Bijzet J; van der Meer JW; Simon A;
Amyloid; 2005 Jun; 12(2):115-9. PubMed ID: 16011988
[TBL] [Abstract][Full Text] [Related]
19. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.
Ozawa M; Komatsuda A; Ohtani H; Nara M; Sato R; Togashi M; Takahashi N; Wakui H
Clin Exp Nephrol; 2017 Apr; 21(2):212-227. PubMed ID: 27116248
[TBL] [Abstract][Full Text] [Related]
20. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis.
De Beer FC; Mallya RK; Fagan EA; Lanham JG; Hughes GR; Pepys MB
Lancet; 1982 Jul; 2(8292):231-4. PubMed ID: 6124669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
